Javelin sues after contamination issues prompt Hospira to delay takeover
This article was originally published in Scrip
Executive Summary
Javelin Pharmaceuticals has filed suit in an attempt to force Hospira to complete its planned $145 million takeover and hand over a promised $2 million loan. The firm went to court after Hospira extended its tender offer for the second time, citing manufacturing issues which prompted a recall of Javelin's Dyloject (diclofenac injection) by Therabel, Javelin's commercial licensing partner in the UK.